| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Catherine Schairer | Q90057571 |
| Bingshu E. Chen | Q56027887 | ||
| P2093 | author name string | Paul H Levine | |
| William F Anderson | |||
| Kenneth W Hance | |||
| P2860 | cites work | The age distribution of cancer and a multi-stage theory of carcinogenesis | Q24564904 |
| The molecular biology of cancer | Q28199928 | ||
| Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. | Q30620197 | ||
| A progression puzzle | Q33337505 | ||
| Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute | Q33751139 | ||
| The role of blood group antigens in malignant progression, apoptosis resistance, and metastatic behavior | Q34072184 | ||
| Pregnancy-associated breast cancer: a case-control study in a young population with a high-fertility rate | Q34103609 | ||
| Population-based statistics for women diagnosed with inflammatory breast cancer (United States). | Q34314328 | ||
| Increasing evidence for a human breast carcinoma virus with geographic differences | Q34340335 | ||
| Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases | Q34659677 | ||
| Acute Mammary Carcinoma: (Volkmann's Mastitis Carcinimatosa). | Q35060700 | ||
| A two-stage theory of carcinogenesis in relation to the age distribution of human cancer | Q36132593 | ||
| Blood group antigens as tumor markers, parasitic/bacterial/viral receptors, and their association with immunologically important proteins | Q38580045 | ||
| Treatment of patients with inflammatory breast cancer | Q38619096 | ||
| Inflammatory carcinoma of the breast | Q78787794 | ||
| Variation in breast cancer counts using SEER and IARC multiple primary coding rules | Q79769558 | ||
| Carcinoma of the breast; results from statistical research | Q80249197 | ||
| Inflammatory carcinoma of the breast | Q80320480 | ||
| Possible relationship between menopause and age at onset of breast cancer | Q80678502 | ||
| V. A Study of Carcinoma Mastitoides | Q81275824 | ||
| Inflammatory breast carcinoma: a distinct entity? | Q93662436 | ||
| Histopathological features of rapidly progressing breast carcinoma in Tunisia: A study of 94 cases | Q38954110 | ||
| Increased incidence of mouse mammary tumor virus-related antigen in Tunisian patients with breast cancer | Q39173168 | ||
| Studies on the role of cellular immunity and genetics in the etiology of rapidly progressing breast cancer in tunisia | Q39173171 | ||
| Epidemiologic features of rapidly progressing breast cancer in Tunisia | Q39275701 | ||
| Rapidly progressing breast cancer (poussée évolutive) in Tunisia: studies on delayed hypersensitivity | Q39275704 | ||
| Breast cancer in women under 30 years of age. | Q39504136 | ||
| Clinical and prognostic features of a rapidly progressing breast cancer in Tunisia | Q39504141 | ||
| Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. | Q40497303 | ||
| Inflammatory breast cancer and body mass index | Q40832138 | ||
| Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk | Q40862149 | ||
| Blood group antigens: molecules seeking a function? | Q40904698 | ||
| Rapidly progressing breast cancer in Nigeria | Q41467137 | ||
| Immunological enhancement of breast cancer | Q41757414 | ||
| Bilateral Thoracic Zosteroid Spreading Marginate Telangiectasia-probably a Variety of "Carcinoma Erysipelatodes" (C. Rasch)-associated with Unilateral Mammary Carcinoma, and better termed "Carcinoma Telangiectaticum". | Q41841709 | ||
| Clinically occult inflammatory carcinoma of the breast | Q43503585 | ||
| Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database | Q43514165 | ||
| Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience | Q43885631 | ||
| Prognostic significance of exclusive skeletal metastases in stage IV primary carcinoma of the breast | Q43913791 | ||
| Age distribution of histologic types of breast carcinoma | Q43952114 | ||
| Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy | Q45105845 | ||
| Inflammatory local recurrence after breast-conservation therapy for noninflammatory breast cancer | Q46630459 | ||
| Breast cancer in Tunisia: clinical and epidemiological study | Q46749460 | ||
| Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. | Q46901734 | ||
| Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. | Q50709872 | ||
| Hazard function estimation using B-splines. | Q52332261 | ||
| Sex chromatin (Barr body) and inflammatory carcinoma of the breast. | Q52951357 | ||
| Inflammatory breast carcinoma: the sphinx of breast cancer research. | Q52958512 | ||
| Breast cancer--not just whether but when? | Q53403582 | ||
| Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. | Q53408408 | ||
| Inflammatory carcinoma of the breast.A Pathologic Definition | Q54475390 | ||
| Inflammatory Breast Carcinoma and Noninflammatory Locally Advanced Breast Carcinoma: Distinct Clinicopathologic Entities? | Q60148921 | ||
| Inflammatory Breast Cancer Survival: The Role of Obesity and Menopausal Status at Diagnosis | Q60148922 | ||
| Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition? | Q63322820 | ||
| Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. | Q64921032 | ||
| Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR | Q64999779 | ||
| Inflammatory carcinoma of the breast | Q67316153 | ||
| Secondary inflammatory breast cancer: treatment options | Q67985473 | ||
| Inflammatory carcinoma of the breast | Q68026877 | ||
| Inflammatory carcinoma of the breast | Q68702537 | ||
| Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance | Q69367626 | ||
| Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program | Q69833744 | ||
| Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). II. Relation of local breast recurrence to multicentricity | Q69855872 | ||
| Estrogen receptor status in inflammatory breast carcinoma | Q70433597 | ||
| Inflammatory tumors of the human breast: determination of estrogen and progesterone receptors | Q71371563 | ||
| Breast cancer | Q71987775 | ||
| Mammographic patterns of inflammatory breast carcinoma: a retrospective study of 92 cases | Q73209838 | ||
| Inflammatory carcinoma of the breast in the male patient | Q73347036 | ||
| Inflammatory breast carcinoma: pathological or clinical entity? | Q73494204 | ||
| Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group | Q73734330 | ||
| The age distribution in female breast and genital cancers | Q73819862 | ||
| P921 | main subject | inflammation | Q101991 |
| inflammatory breast cancer | Q5922406 | ||
| epidemiology | Q133805 | ||
| P304 | page(s) | 9-23 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Breast Disease | Q15750960 |
| P1476 | title | Epidemiology of inflammatory breast cancer (IBC) | |
| P478 | volume | 22 |
| Q36546465 | A comparison of cholesterol uptake and storage in inflammatory and noninflammatory breast cancer cells |
| Q30724470 | A comparison of criteria to identify inflammatory breast cancer cases from medical records and the Surveillance, Epidemiology and End Results data base, 2007-2009. |
| Q36514752 | A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. |
| Q34147662 | Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling |
| Q33636065 | Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients |
| Q37725631 | Anti-RhoC siRNAs inhibit the proliferation and invasiveness of breast cancer cells via modulating the KAI1, MMP9, and CXCR4 expression |
| Q35662191 | Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007. |
| Q47769924 | BRCA mutations in women with inflammatory breast cancer |
| Q38133058 | Breast cancer in Arab populations: molecular characteristics and disease management implications |
| Q55322297 | CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. |
| Q33622291 | Cancer diagnosis in primary care |
| Q50421633 | Cancer in Guam and Hawaii: A comparison of two U.S. Island populations |
| Q36598732 | Characterizing inflammatory breast cancer among Arab Americans in the California, Detroit and New Jersey Surveillance, Epidemiology and End Results (SEER) registries (1988-2008). |
| Q36790725 | Chronic inflammation and breast cancer recurrence |
| Q37015722 | Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. |
| Q33829270 | Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer |
| Q54967454 | Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. |
| Q90057587 | Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa |
| Q28554790 | Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine |
| Q51901480 | Coping with Inflammatory Breast Cancer: Women's Experiences |
| Q28075322 | Developmental therapeutics for inflammatory breast cancer: Biology and translational directions |
| Q39021097 | Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer. |
| Q35006619 | Differences in Reliability of Reproductive History Recall Among Women in North Africa |
| Q39746375 | Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer |
| Q58701459 | Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center |
| Q36386871 | Epidemiology of triple negative breast cancers |
| Q35007782 | Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer |
| Q31138996 | Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells |
| Q37072265 | ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells |
| Q55332314 | Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer. |
| Q89782152 | Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer |
| Q33616254 | Geospatial Analysis of Inflammatory Breast Cancer and Associated Community Characteristics in the United States |
| Q35951359 | Glucocorticoid receptor expression in breast cancer associates with older patient age |
| Q34769223 | High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt |
| Q37451898 | High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer |
| Q37092688 | Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells |
| Q88675564 | Immediate breast reconstruction for women having inflammatory breast cancer in the United States |
| Q34558393 | Immunologic targeting of FOXP3 in inflammatory breast cancer cells. |
| Q36031290 | Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study |
| Q37627127 | Incidence of inflammatory breast cancer in women, 1992-2009, United States |
| Q36020234 | Inflammatory Breast Carcinoma Presenting with Two Different Patterns of Cutaneous Metastases: Carcinoma Telangiectaticum and Carcinoma Erysipeloides |
| Q34918360 | Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008. |
| Q63366138 | Inflammatory breast cancer biology: the tumour microenvironment is key |
| Q84303245 | Inflammatory breast cancer in Italy: epidemiological and clinical aspects |
| Q47442617 | Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician |
| Q34918207 | Inflammatory breast cancer in north Africa: comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco |
| Q35115896 | Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer |
| Q61454329 | Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy |
| Q27028128 | Inflammatory breast cancer: what we know and what we need to learn |
| Q36703133 | Inflammatory breast carcinoma |
| Q55122090 | Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer. |
| Q42618816 | Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study |
| Q40887298 | MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. |
| Q35572495 | Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients |
| Q33618285 | Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients |
| Q37989260 | Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study |
| Q37431789 | Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy |
| Q34478105 | Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis |
| Q61451208 | Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics |
| Q92746974 | Prevalence of germline variants in inflammatory breast cancer |
| Q34640608 | Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from algeria compared with other types of breast cancer tumors |
| Q54976875 | RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis. |
| Q45067157 | Racial and Socioeconomic Disparities Are More Pronounced in Inflammatory Breast Cancer Than Other Breast Cancers |
| Q35413280 | Residential environment and breast cancer incidence and mortality: a systematic review and meta-analysis |
| Q37180368 | Risk factors for inflammatory breast cancer and other invasive breast cancers |
| Q34917731 | Survival of inflammatory breast cancer patients compared to non-inflammatory breast cancer patients in Egypt |
| Q28066752 | The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms |
| Q55405935 | The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study. |
| Q36725203 | The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells |
| Q87197957 | The need for post-mastectomy radiotherapy in patients with IBC |
| Q34419629 | The role of inflammation in inflammatory breast cancer. |
| Q88965519 | Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers |
| Q33796162 | Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database |
| Q37210821 | What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma? |
Search more.